The inhibition of FAK using genetic (FAK shRNA transduction) or pharmacological (FAK TKI) methods radiosensitized KRAS-mutated NSCLC significantly decreased radiation survival in vitro and in vivo [215]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.